Development & Commercialization of Antibacterial Drugs to Speed Up

The growing threat posed by multi-drug resistant gram-negative organisms (MDR-GNBs) is lending a sense of urgency to the development of antibacterial drugs worldwide. Upcoming regulatory reforms to lower R&D costs and provide incentives for new drug identification will create attractive opportunities for pharmaceutical manufacturers.

New analysis from Frost & Sullivan, A Product and Pipeline Analysis of the Antibacterial Drugs Market, finds that nearly 80% of drugs currently in the pipeline are from smaller pharmaceutical and biotech companies, of which half do not have any commercialized products in the market. GlaxoSmithKline, AstraZeneca, and Merck & Co are the only three established pharmaceutical organizations in the antibacterial drug space.

“Thirty eight antibacterial drugs currently under development have the potential to address many, but not all, resistant bacteria,” said Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. “Plazomicin and Eravacycline are two emerging compounds that have a broad-spectrum activity against most MDR-GNBs.”

Discovering new antibacterial drugs and identifying novel compounds that can successfully target bacteria is scientifically challenging. Given the high probability of failure and steep research and development (R&D) costs, big pharma companies that were once leaders are closing down their antibacterial research facilities.

Agencies such as the Food and Drug Administration (FDA) and the Infectious Diseases Society of America are deploying several initiatives to lure companies back into antibacterial R&D. The recently implemented Generating Antibiotic Incentives Now (GAIN) Act is expected to facilitate more efficient clinical studies and reduce barriers to market entry. In Europe, the Innovative Medicines Initiative (IMI) has launched two projects – Combatting Bacterial Resistance in Europe (COMBACTE) and TRANSLOCATION (molecular basis of the bacterial cell wall permeability) – that showcase an unprecedented partnership between industry, biotech organizations, and academia to fight antibiotic resistance.

“Further, collaborations in the form of public-private partnerships among industry, academia, investors and key opinion leaders will effectively address the vast unmet clinical and commercial needs in the antibacterial drugs market and quicken the journey towards commercialization,” concluded Chidambaram.

A Product and Pipeline Analysis of the Antibacterial Drugs Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan’s related studies include: A Competitive Analysis of the Global Breast Cancer Therapeutics Market, A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market, A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market, and Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/EU_PR_AZanchi_MABA-52_20Mar15.

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

​